BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35832830)

  • 21. Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study.
    Hong ZN; Weng K; Peng K; Chen Z; Lin J; Kang M
    Front Oncol; 2021; 11():797426. PubMed ID: 34970498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.
    Chen P; Wang L; Yang X; Feng J
    Biomol Biomed; 2024 Jan; 24(1):159-169. PubMed ID: 37597214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A propensity score-matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma.
    Wang K; Liang Y; Huang J; Xie X; Wu D; Chen B; Wang K; Shen Z; Li Y; Wang W; Hu X; Wang M
    J Surg Oncol; 2023 Aug; 128(2):207-217. PubMed ID: 37036218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.
    Cheng D; Zhao W; Chen R; Li D; Tang S; Fang C; Ji M
    World J Surg Oncol; 2023 Feb; 21(1):33. PubMed ID: 36737768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Qiu Q; Duan J; Deng H; Han Z; Gu J; Yue NJ; Yin Y
    Front Oncol; 2020; 10():1398. PubMed ID: 32850451
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical significance of geriatric nutritional risk index in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Eur J Surg Oncol; 2024 Jun; 50(6):108323. PubMed ID: 38603867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
    Gao L; Hong ZN; Wu L; Yang Y; Kang M
    Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A CT-based novel model to predict pathological complete response of locally advanced esophageal squamous cell carcinoma to neoadjuvant PD-1 blockade in combination with chemotherapy.
    Zhou HY; Guo WW; Ou J; Li R; Gui Y; Li L; Fu MY; Zhang XM; Chen TW
    Eur J Radiol; 2023 Oct; 167():111065. PubMed ID: 37651827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Body Composition on Clinical Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Plus Chemotherapy.
    Zhao Y; Xia M; Dang Y; Li Y; Zhao X; Kang N; Zuo J; Zhang R
    Ann Ital Chir; 2024; 95(3):284-293. PubMed ID: 38918965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nomogram for Predicting Occult Locally Advanced Esophageal Squamous Cell Carcinoma Before Surgery.
    Huang Z; Hong Z; Chen L; Kang M
    Front Surg; 2022; 9():917070. PubMed ID: 35774392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated Preoperative NMPR Predicts an Unfavorable Chance of Survival in Resectable Esophageal Squamous Cell Carcinoma.
    Peng MY; Zuo ZG; Cao FJ; Yu YD; Cai XJ; Wan GX
    Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis.
    Wang H; Li S; Liu T; Chen J; Dang J
    Front Immunol; 2022; 13():998620. PubMed ID: 36177019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of inflammatory nutritional scores in locally advanced esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multicenter study in China.
    Xu J; Hong Z; Cai Y; Chen Z; Lin J; Yuan X; Chen S; Xie J; Kang M; Ke S
    Front Oncol; 2024; 14():1279733. PubMed ID: 38463231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and Validation of a New Integrative Score Based on Various Systemic Inflammatory and Nutritional Indicators in Predicting Prognosis in Patients With Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.
    Feng JF; Wang L; Chen QX; Yang X
    Cancer Control; 2022; 29():10732748221091394. PubMed ID: 35410489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Ding T; Liu C; Huang B; Chu L; Wei L; Lin Y; Luo Y; Zhang B; Hong C; Xu Y; Peng Y
    Cancer Manag Res; 2021; 13():7771-7782. PubMed ID: 34675672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alleviation of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma and its relationship with expression and changes of PD-L1.
    Zhou YH; Li JY; Yan JX; Guo P; He WW; Liu Y
    Neoplasma; 2022 Jul; 69(4):785-793. PubMed ID: 35400168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A nomogram based on pretreatment CT radiomics features for predicting complete response to chemoradiotherapy in patients with esophageal squamous cell cancer.
    Luo HS; Huang SF; Xu HY; Li XY; Wu SX; Wu DH
    Radiat Oncol; 2020 Oct; 15(1):249. PubMed ID: 33121507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of Osaka prognostic score based on nutritional and inflammatory status in patients with esophageal squamous cell carcinoma.
    Feng J; Wang L; Wang L; Yang X; Lou G
    BMC Cancer; 2022 Mar; 22(1):284. PubMed ID: 35300627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers.
    Wu Y; Chen J; Zhao L; Li Q; Zhu J; Yang H; Guo S; Xi M
    Cancer Res Treat; 2021 Jan; 53(1):172-183. PubMed ID: 32898941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma.
    Zhao K; Wang C; Shi F; Li M; Yu J
    Transl Cancer Res; 2020 Jun; 9(6):3842-3853. PubMed ID: 35117751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.